{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Hematologic - Any Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hematologic - Any Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hematologic - Any Grade 5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Non-Hematologic - Any Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Non-Hematologic - Any Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Non-Hematologic - Any Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Participants with Grade 3, 4, and 5 toxicities possibly, probably, or definitely related to study treatment. Toxicity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).","groups":[{"description":"Participants received AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"AZD6244 (Selumetinib) Treatment"}],"paramType":"NUMBER","populationDescription":"All participants who received study treatment","reportingStatus":"POSTED","timeFrame":"1 year, 11 months","title":"Incidence of Toxicity That May Be Treatment Emergent","type":"SECONDARY","unitOfMeasure":"participants"}